gwp42003-p
Dravet Syndrome
Jazz PharmaceuticalsPhase 3Dormant
BB
67/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 56/ 100
- Competitive Position
- 89/ 100
Competitive context
11 Active assets in the Dravet Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Benzeneethanamine, N-ethyl-?-methyl-4-(trifluoromethyl)-, hydrochloride, (±)- The University of Texas Health Science Center, Houston | Phase 4 | BBB |
Bexicaserin Longboard Pharmaceuticals | Phase 3 | BB |
Zorevunersen Stoke Therapeutics, Inc | Phase 3 | BB |
Clemizole Epygenix | Phase 3 | BB |
Soticlestat Takeda | Phase 3 | B |
View all 15 →
Same molecule, other indications
gwp42003-p is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →